Brompheniramine maleate 8 mg Extended Release Oral Tablet [Dimetane Extentab]
RxNorm 1357401

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1357401 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: brompheniramine maleate 8 mg Extended Release Oral Tablet [Dimetane Extentab].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBD
Brompheniramine maleate 8 mg Extended Release Oral Tablet [Dimetane Extentab]
AUI:12371063
View
SY
Dimetane Extentab 8 mg Extended Release Oral Tablet
AUI:6353802
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBD

Semantic Branded Drug (SBD):
Brompheniramine maleate 8 mg Extended Release Oral Tablet [Dimetane Extentab]
(Atom ID: 12371063)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
brompheniramine maleate 8 MG Extended Release Oral Tablet [Dimetane Extentab]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1357401
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12371063
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBD
Semantic Branded Drug (Ingredient + Strength + Dose Form + Brand Name)
Source Code
1357401
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN OBSOLETED
04/30/2020
Date the RxNorm atom became obsolete
SY

Synonym (SY):
Dimetane Extentab 8 mg Extended Release Oral Tablet
(Atom ID: 6353802)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Dimetane Extentab 8 MG Extended Release Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1357401
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
6353802
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1357401
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.